Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents.
about
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.Evolution of systemic therapy for advanced pancreatic cancer.Pancreatic cancer--is the wall crumbling?Gemcitabine in the treatment of metastatic pancreatic cancer.Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells.Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
P2860
Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Newer approaches to gemcitabin ...... ate infusion and novel agents.
@ast
Newer approaches to gemcitabin ...... ate infusion and novel agents.
@en
type
label
Newer approaches to gemcitabin ...... ate infusion and novel agents.
@ast
Newer approaches to gemcitabin ...... ate infusion and novel agents.
@en
prefLabel
Newer approaches to gemcitabin ...... ate infusion and novel agents.
@ast
Newer approaches to gemcitabin ...... ate infusion and novel agents.
@en
P1476
Newer approaches to gemcitabin ...... ate infusion and novel agents.
@en
P2093
Howard S Hochster
P356
10.1016/S0360-3016(03)00447-4
P407
P433
P577
2003-01-01T00:00:00Z